JP2003522782A5 - - Google Patents

Download PDF

Info

Publication number
JP2003522782A5
JP2003522782A5 JP2001559441A JP2001559441A JP2003522782A5 JP 2003522782 A5 JP2003522782 A5 JP 2003522782A5 JP 2001559441 A JP2001559441 A JP 2001559441A JP 2001559441 A JP2001559441 A JP 2001559441A JP 2003522782 A5 JP2003522782 A5 JP 2003522782A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
treatment
cancer
composition according
mtdc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001559441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522782A (ja
Filing date
Publication date
Priority claimed from DE10008159A external-priority patent/DE10008159B4/de
Application filed filed Critical
Publication of JP2003522782A publication Critical patent/JP2003522782A/ja
Publication of JP2003522782A5 publication Critical patent/JP2003522782A5/ja
Pending legal-status Critical Current

Links

JP2001559441A 2000-02-15 2001-02-15 2−メチル−チアゾリジン−2,4−ジカルボン酸及び/又はその生理学的に許容できる塩の抗がん剤としての使用 Pending JP2003522782A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10008159A DE10008159B4 (de) 2000-02-15 2000-02-15 Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel
DE10008159.2 2000-02-15
PCT/DE2001/000656 WO2001060343A2 (de) 2000-02-15 2001-02-15 Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen

Publications (2)

Publication Number Publication Date
JP2003522782A JP2003522782A (ja) 2003-07-29
JP2003522782A5 true JP2003522782A5 (enExample) 2005-04-14

Family

ID=7631906

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001559441A Pending JP2003522782A (ja) 2000-02-15 2001-02-15 2−メチル−チアゾリジン−2,4−ジカルボン酸及び/又はその生理学的に許容できる塩の抗がん剤としての使用

Country Status (15)

Country Link
US (2) US6943185B2 (enExample)
EP (1) EP1255538B1 (enExample)
JP (1) JP2003522782A (enExample)
CN (1) CN1400899A (enExample)
AT (1) ATE252383T1 (enExample)
AU (1) AU783933B2 (enExample)
CA (1) CA2399709C (enExample)
DE (2) DE10008159B4 (enExample)
EA (1) EA004592B1 (enExample)
ES (1) ES2208571T3 (enExample)
MX (1) MXPA02007903A (enExample)
PL (1) PL357179A1 (enExample)
PT (1) PT1255538E (enExample)
TR (1) TR200302134T4 (enExample)
WO (1) WO2001060343A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197406A1 (en) * 1999-04-14 2005-09-08 Li Chiang J. Method of treatment of lung cancer
DE10008159B4 (de) * 2000-02-15 2005-08-18 Rudy Dr. Susilo Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel
CN101838218A (zh) * 2002-02-28 2010-09-22 日本烟草产业株式会社 酯化合物及其医药用途
WO2005021486A1 (ja) * 2003-08-29 2005-03-10 Japan Tobacco Inc. エステル誘導体及びその医薬用途
DE102004021658A1 (de) * 2004-05-03 2005-12-01 Rudy Dr. Susilo Kombinationspräparate enthaltend 2-Methylthiazolidin-2,4-dicarbonsäure
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
JP5439849B2 (ja) * 2008-02-28 2014-03-12 味の素株式会社 システイン誘導体
JP5378713B2 (ja) * 2008-06-19 2013-12-25 日本理化学薬品株式会社 外用組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19711053C2 (de) * 1997-03-03 1999-09-02 Rommelspacher Kombinationspräparat aus 2-Methyl-thiazolidin-2,4-dicarbonsäure und Paracetamol
DE19711052C2 (de) * 1997-03-03 1999-09-23 Hans Rommelspacher Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure als Mukolytikum
DE10008159B4 (de) * 2000-02-15 2005-08-18 Rudy Dr. Susilo Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel

Similar Documents

Publication Publication Date Title
JP2006523216A5 (enExample)
JP2006143751A5 (enExample)
WO2002070510A3 (de) Aminodicarbonsäurederivate mit pharmazeutischen eigenschaften
EP2298416A3 (en) Sustained-release tramadol formulations with 24-hour clinical efficacy
ATE361077T1 (de) Indanylderivate zur behandlung von atemwegserkrankungen
CN1878757A (zh) 吡啶酮衍生物及其应用
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
JP2006182786A5 (enExample)
JP2006526590A5 (enExample)
JP2003522782A5 (enExample)
WO2005107719A3 (en) Pharmaceutical composition comprising hydrophobic drug having improved solubility
NZ547592A (en) Florfenicol prodrug having improved water solubility
JP2009500423A5 (enExample)
JP2010513487A5 (enExample)
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
JP2006527185A5 (enExample)
JP2004532828A5 (enExample)
JP2005511619A5 (enExample)
PL356932A1 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
JP2010500284A5 (enExample)
WO2005110413A3 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
WO2008020269A3 (en) A method of treating tumors with azaxanthones
JP4395368B2 (ja) 細胞殺傷活性を有するカルシウム塩
JP2005523269A5 (enExample)